26 Feb VaxNewMo’s Vaccine Breakthrough Published In Nature
The BioGenerator-backed startup and Arch Grant recipient gets highlighted by Nature Communications for its ‘promising process’ to more quickly and affordably bring vaccines to market.
St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with its patented technology. The company’s breakthrough research is currently featured in Nature Magazine’s Communications section.
Publication in this major peer-reviewed journal validates VaxNewMo’s technology and highlights its findings in the article, “A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host.”